Leerink Partnrs Has Negative Outlook of KYMR FY2025 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Equities research analysts at Leerink Partnrs decreased their FY2025 EPS estimates for Kymera Therapeutics in a research note issued on Tuesday, November 4th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings of ($3.63) per share for the year, down from their previous forecast of ($3.61). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics’ Q4 2025 earnings at ($0.95) EPS, Q1 2026 earnings at ($0.99) EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.03) EPS and FY2026 earnings at ($4.09) EPS.

Other equities analysts have also issued research reports about the company. Guggenheim began coverage on Kymera Therapeutics in a research note on Monday. They issued a “buy” rating and a $90.00 price objective for the company. Morgan Stanley restated an “overweight” rating and issued a $73.00 price target on shares of Kymera Therapeutics in a research note on Tuesday. Oppenheimer reiterated an “outperform” rating and set a $67.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company lifted their target price on Kymera Therapeutics from $53.00 to $69.00 and gave the stock an “overweight” rating in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $69.75.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock opened at $61.00 on Friday. Kymera Therapeutics has a fifty-two week low of $19.44 and a fifty-two week high of $63.96. The company has a market capitalization of $4.39 billion, a P/E ratio of -16.99 and a beta of 2.32. The company has a fifty day moving average of $53.84 and a 200 day moving average of $44.88.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The firm had revenue of $2.76 million during the quarter, compared to analysts’ expectations of $23.15 million. Kymera Therapeutics had a negative return on equity of 32.92% and a negative net margin of 674.81%.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC boosted its stake in shares of Kymera Therapeutics by 642.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after purchasing an additional 540 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after buying an additional 770 shares during the period. Bessemer Group Inc. boosted its position in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after buying an additional 815 shares during the period. Osaic Holdings Inc. grew its stake in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Kymera Therapeutics in the second quarter worth approximately $73,000.

Insider Buying and Selling

In other news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $60.99, for a total value of $1,829,700.00. Following the completion of the sale, the chief executive officer directly owned 660,482 shares of the company’s stock, valued at $40,282,797.18. This trade represents a 4.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jared Gollob sold 59,576 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $61.42, for a total value of $3,659,157.92. Following the transaction, the insider directly owned 109,992 shares in the company, valued at approximately $6,755,708.64. This represents a 35.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 206,910 shares of company stock valued at $11,402,648. 16.01% of the stock is currently owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.